Development of Chromatographic Method for Determination of Drugs Reducing Cholesterol Level--statins and Ezetimibe.

نویسندگان

  • Elżbieta Kublin
  • Ewa Malanowicz
  • Barbara Kaczmarska-Graczyk
  • Krystyna Czerwińska
  • Elżbieta Wyszomirska
  • Aleksander P Mazurek
چکیده

The presented developed HPLC method and GC method may be used to separate and determine all analyzed 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and ezetimibe using a single columns and a uniform methodology. In order to perform qualitative and quantitative tests of statins and ezetimibe the Symmetry C18 column 250 mm x 4.6 mm, 5 µm, the mobile phase: acetonitrile:water (70:30, v/v), adjusted to pH = 2.5 and a spectrophotometric detector for the HPLC method were used. For GC method column HP-1; 30 m x 0.25 mm x 0.25 µm and FID detector were selected. All results and statistical data obtained indicate good method sensitivity and precision. The RSD values are appropriate for both newly developed methods.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

High performance liquid chromatographic method for determination of ezetimibe in pharmaceutical formulation tablets

Ezetimide belongs to a class of lipid lowering    compounds    that    selectively    inhibits intestinal   absorption   of   cholesterol   and   related phytosterols. The purpose of this study is to establish a reliable and quick method for the assignment of ezetimibe in tablets form b...

متن کامل

Development of chromatographic method for determination of drugs reducing cholesterol level.

Hyperlipidemia (HLP) is a group of lipid metabolism disorders with various pathogenesis. Its characteristic feature is an increase in cholesterol level, especially the low density lipoprotein fraction (LDL) level or triglyceride level in blood. An increase in total and LDL cholesterol level is related to the increased risk of ischemic heart disease as well as cerebral, coronary and peripheral c...

متن کامل

Beyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?

Given the close relationship between serum cholesterol and cardiovascular risk, it is unsurprising that lipid-lowering therapy has been shown to markedly reduce cardiovascular events in various studies of diverse populations at cardiovascular risk [1–3]. There is up to a 19% reduction in cardiovascular events for every 1.0-mmol reduction in the level of low-density-lipoprotein cholesterol (LDL-...

متن کامل

Role of Colesevelam in Combination Lipid-Lowering Therapy

Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy ...

متن کامل

Ezetimibe plus a Statin after Acute Coronary Syndromes

To the Editor: With regard to the article by Cannon et al. (June 18 issue),1 human serum cholesterol derives from two sources: it is either synthesized endogenously or absorbed in the intestine. Statins inhibit endogenous cholesterol synthesis, whereas ezetimibe inhibits intestinal cholesterol absorption.2 According to findings from the Scandinavian Simvastatin Survival Study3 and the German Di...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Acta poloniae pharmaceutica

دوره 72 3  شماره 

صفحات  -

تاریخ انتشار 2015